Perspectives in Melanoma XIII

Aktivní účast

• Online podávání abstrakt do 17. srpna 2009

Registrace

• Zlevněná registrace do 6. srpna 2009
• Běžná registrace do 1. října 2009
• Online registrace
• 1. oznámení

Thursday, October 8, 2009
8:30 am Welcome Address
John M. Kirkwood, MD

Session I: Epidemiology, genetics, and prevention
Moderator: Susan M. Swetter, MD

8:45 am Increasing burden of melanoma in young women: What’s really going on?
Speaker invited

9:05 am Differential effects of UVA and UVB radiation: Moles versus malignancy
Speaker invited

9:30 am Current understanding of the genetics of melanoma
Sancy A. Leachman, MD, PhD

9:55 am The role of p16 testing in patients at high-risk for melanoma
Sancy A. Leachman, MD, PhD

10:15 am Does regular use of NSAIDs protect against melanoma? Updates on chemoprevention in melanoma
Clara Curiel-Lewandrowski, MD

10:40 am Panel discussion

10:50 am Break

Session II: Detection and prognosis Moderator: John M. Kirkwood, MD

11:10 am Optical imaging and diagnosis of melanoma: Where we are today and where we may be tomorrow
Allan C. Halpern, MD

11:40 am Molecular diagnosis of melanoma
Mohammed Kashani-Sabet, MD

12:05 pm Prognostic significance of lymphatic invasion in primary melanomas
George Xu, MD, PhD

12:25 pm Panel discussion

12:35 pm Lunch

Session III: Abstract session I

1:45 pm Oral presentation of selected abstracts

2:45 pm Break

Session IV: Surgery and staging

3:05 pm The new AJCC staging system
Charles Balch, MD, FACS

3:25 pm The lymphovascular compartment, and its assessment with miRNA technology
Soheil Sam Dadras MD, PhD

3:45 pm Panel discussion

4:00 pm Adjourn

Friday, October 9, 2009
8:30 am Introduction to day two

Session V: Immunomodulation

8:40 am Molecular insights upon toll-like receptor agonists and vaccination in melanoma
Hassane Zarour, MD

9:00 am Tumor localization of T-cells
Thomas Gajewski, MD, PhD

9:20 am Current status of PD-1 interventions for melanoma and other solid tumors
Suzanne Topalian, MD

9:40 am GM-CSF as an immunologic adjuvant in human cancer vaccines
Craig L. Slingluff, Jr., MD

10:00 am Panel discussion

10:15 am Break

Session VI: Abstract Session II

10:45 am Oral presentation of selected abstracts

11:45 am Lunch

1:00 pm Special address to the melanoma community
Valerie Guild, The Aim at Melanoma Foundation

Friday, October 9, 2009 (cont'd)
Session VII: Emerging molecular targets in melanoma
Moderator: Keith Flaherty, MD

1:20 pm Mouse model(s) to guide drug development/discovery of novel therapeutic targets
Marcus Bosenberg, MD

1:40 pm Targeting C-Kit in celanoma — DFCI experience and overview of current trials
F. Stephen Hodi, MD

2:00 pm Therapeutic targeting of the MAP kinase pathway in melanoma
Igor Puzanov, MD

2:20 pm Break

2:40 pm Options to target the PI3K pathway for therapy of melanoma
Ben Ho Park, MD, PhD

3:00 pm CDK inhibitors—rationale and prospects for future therapeutic intervention
Stergios Moschos, MD

3:20 pm Targeting angiogenesis with VEGF TRAP in melanoma (results of a CCC phase II trial)
Ahmad Tarhini, MD, MSc

3:40 pm The potential of combinations of agents for targeted therapy of melanoma
Kerrington Molhoek, MD

4:00 pm Panel discussion

4:15 pm Adjourn

Saturday, October 10, 2009
8:30 am Introduction to day three

Session VIII: Special topics in melanoma

8:40 am Drug resistance and its abrogation
Hussein Tawbi, MD

9:00 am Molecular analysis of resistance to non-classical aklylators: New options for improved cytotoxic therapy of melanoma
Speaker invited

9:20 am Management of site-specific metastasis
Jeffrey E. Gershenwald, MD

9:40 am Break

Session IX: Abstract Session III

10:00 am Oral presentation of selected abstracts

Session X: Clinical trial updates

11:00 am E4697
David H. Lawson, MD

11:20 am SYMMETRY
Steven J. O'Day, MD

11:40 am E2603
Keith T. Flaherty, MD

12:00 pm BEAM
Kevin B. Kim, MD

12:20 pm Discussion

12:30 pm Adjourn

Kontakt: meetings@imedex.com

Web: http://www.imedex....paign=Live20090507+